Risk of mortality and cancer incidence in Barrett's esophagus - PubMed (original) (raw)
Risk of mortality and cancer incidence in Barrett's esophagus
Michael B Cook et al. Cancer Epidemiol Biomarkers Prev. 2007 Oct.
Abstract
Background: There are very few prospective follow-up studies of Barrett esophagus (BE) cohorts assessing the risk of extraesophageal cancer incidence or mortality. Such studies are necessary in order to understand the overall risks of cancer and death experienced by patients with BE.
Methods: A cohort of 502 patients with BE were identified at Leeds General Infirmary, England. Mortality and cancer incidence information were provided by the Office for National Statistics. Standardized mortality ratios (SMR) and standardized incidence ratios (SIR) were calculated using indirect standardization.
Results: All-cause mortality was found to be elevated in patients with BE [SMR, 1.21; 95% confidence interval (95% CI), 1.06, 1.37] and remained so after esophageal cancers were excluded (SMR, 1.16; 95% CI, 1.01-1.32). Increased mortality risks were also found for malignant neoplasms of the esophagus (SMR, 7.26; 95% CI, 3.87-12.42) and diseases of the digestive system (SMR, 2.03; 95% CI, 1.11-3.40). The remaining disease categories produced no altered risk estimates. Circulatory disease mortality was borderline statistically significant (SMR, 1.24; 95% CI, 1.00-1.52; P = 0.053) for those with a specialized intestinal metaplasia diagnosis of BE. In the cancer incidence analyses, esophageal malignancies (SIR, 8.66; 95% CI, 4.73-14.53) and esophageal adenocarcinomas (SIR, 14.29; 95% CI, 7.13-22.56) were found to be increased in BE. All remaining analyses provided unaltered risks, including that of colorectal cancer.
Conclusions: This study has shown evidence of an increased risk of esophageal cancer incidence and mortality in BE. It has also shown that those who have a histologic BE diagnosis may also have an increased risk of circulatory disease mortality.
Similar articles
- Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus.
Schouten LJ, Steevens J, Huysentruyt CJ, Coffeng CE, Keulemans YC, van Leeuwen FE, Driessen AL, van den Brandt PA. Schouten LJ, et al. Clin Gastroenterol Hepatol. 2011 Sep;9(9):754-61. doi: 10.1016/j.cgh.2011.04.008. Epub 2011 Apr 15. Clin Gastroenterol Hepatol. 2011. PMID: 21570484 - Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R, O'Sullivan K, Quigley EM. Quera R, et al. Endoscopy. 2006 Feb;38(2):162-9. doi: 10.1055/s-2005-921184. Endoscopy. 2006. PMID: 16479424 - Mortality in Barrett's esophagus: three decades of experience at a single center.
Caygill CP, Royston C, Charlett A, Wall CM, Gatenby PA, Ramus JR, Watson A, Winslet M, Bardhan KD. Caygill CP, et al. Endoscopy. 2012 Oct;44(10):892-8. doi: 10.1055/s-0032-1309842. Epub 2012 Jul 2. Endoscopy. 2012. PMID: 22752886 - Diagnosis and recognition of early esophageal neoplasia.
Herszényi L, Pregun I, Tulassay Z. Herszényi L, et al. Dig Dis. 2009;27(1):24-30. doi: 10.1159/000210100. Epub 2009 May 8. Dig Dis. 2009. PMID: 19439957 Review. - Surgical therapy for Barrett's esophagus with high-grade dysplasia and early esophageal carcinoma.
Gilbert S, Jobe BA. Gilbert S, et al. Surg Oncol Clin N Am. 2009 Jul;18(3):523-31. doi: 10.1016/j.soc.2009.03.008. Surg Oncol Clin N Am. 2009. PMID: 19500741 Review.
Cited by
- Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry.
Li N, Pasricha S, Bulsiewicz WJ, Pruitt RE, Komanduri S, Wolfsen HC, Chmielewski GW, Corbett FS, Chang KJ, Shaheen NJ. Li N, et al. Dis Esophagus. 2016 Aug;29(6):537-43. doi: 10.1111/dote.12386. Epub 2015 Jun 30. Dis Esophagus. 2016. PMID: 26121935 Free PMC article. - The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis.
Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, El-Serag HB. Fischbach LA, et al. Helicobacter. 2012 Jun;17(3):163-75. doi: 10.1111/j.1523-5378.2011.00931.x. Epub 2012 Mar 20. Helicobacter. 2012. PMID: 22515353 Free PMC article. - Warburg and Crabtree effects in premalignant Barrett's esophagus cell lines with active mitochondria.
Suchorolski MT, Paulson TG, Sanchez CA, Hockenbery D, Reid BJ. Suchorolski MT, et al. PLoS One. 2013;8(2):e56884. doi: 10.1371/journal.pone.0056884. Epub 2013 Feb 27. PLoS One. 2013. PMID: 23460817 Free PMC article. - Barrett's metaplasia and colonic neoplasms: a significant association in a 203,534-patient study.
Sonnenberg A, Genta RM. Sonnenberg A, et al. Dig Dis Sci. 2013 Jul;58(7):2046-51. doi: 10.1007/s10620-013-2565-5. Epub 2013 Jan 31. Dig Dis Sci. 2013. PMID: 23371013 - Barrett's esophagus: where do we stand?
Al Madi MA. Al Madi MA. Saudi J Gastroenterol. 2009 Jan;15(1):2-10. doi: 10.4103/1319-3767.45046. Saudi J Gastroenterol. 2009. PMID: 19568547 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical